These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23135199)

  • 1. Denosumab may reduce hypercalcaemia after transplantation for osteopetrosis.
    BMJ; 2012 Nov; 345():e7477. PubMed ID: 23135199
    [No Abstract]   [Full Text] [Related]  

  • 2. Denosumab for post-transplantation hypercalcemia in osteopetrosis.
    Shroff R; Beringer O; Rao K; Hofbauer LC; Schulz A
    N Engl J Med; 2012 Nov; 367(18):1766-7. PubMed ID: 23113501
    [No Abstract]   [Full Text] [Related]  

  • 3. Resistant hypercalcaemia in metastatic parathyroid carcinoma.
    Bowyer SE; White AM; Ransom DT; Davidson JA
    Med J Aust; 2013 Jun; 198(10):559-61. PubMed ID: 23725272
    [No Abstract]   [Full Text] [Related]  

  • 4. Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction.
    Cicci JD; Buie L; Bates J; van Deventer H
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):e207-11. PubMed ID: 25128013
    [No Abstract]   [Full Text] [Related]  

  • 5. Denosumab for tumor-induced hypercalcemia complicated by renal failure.
    Bech A; de Boer H
    Ann Intern Med; 2012 Jun; 156(12):906-7. PubMed ID: 22711097
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature.
    Freeman A; El-Amm J; Aragon-Ching JB
    Clin Genitourin Cancer; 2013 Dec; 11(4):e24-6. PubMed ID: 24007982
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter to the editor: denosumab for “resistant” hypercalcemia in patients with impaired renal function.
    Arampatzis S
    J Clin Endocrinol Metab; 2015 Jan; 100(1):L6. PubMed ID: 25559545
    [No Abstract]   [Full Text] [Related]  

  • 8. Using denosumab to treat immobilization hypercalcemia in a post-acute care patient.
    Booth KA; Hays CI
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3531-5. PubMed ID: 25033064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
    Adhikaree J; Newby Y; Sundar S
    BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resorptive hypercalcemia in post-essential thrombocythemia myelofibrosis: treatment with denosumab.
    Khoury N; Chang J; Gru AA; Whyte MP
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3051-5. PubMed ID: 22730513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cell transplantation for infantile osteopetrosis.
    Eapen M; Davies SM; Ramsay NK; Orchard PJ
    Bone Marrow Transplant; 1998 Nov; 22(10):941-6. PubMed ID: 9849690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response letter to the editor.
    Hu M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):L7. PubMed ID: 25559546
    [No Abstract]   [Full Text] [Related]  

  • 13. Bisphosphonate or RANK-L inhibitor for tumour-induced hypercalcaemia?
    Bech A; Essink G; de Boer H
    Neth J Med; 2012 Jun; 70(5):250-1. PubMed ID: 22744931
    [No Abstract]   [Full Text] [Related]  

  • 14. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia.
    Boikos SA; Hammers HJ
    J Clin Oncol; 2012 Oct; 30(29):e299. PubMed ID: 22949145
    [No Abstract]   [Full Text] [Related]  

  • 15. Engraftment and survival following hematopoietic stem cell transplantation for osteopetrosis using a reduced intensity conditioning regimen.
    Tolar J; Bonfim C; Grewal S; Orchard P
    Bone Marrow Transplant; 2006 Dec; 38(12):783-7. PubMed ID: 17086207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and management of hypercalcemia following transplantation for osteopetrosis.
    Martinez C; Polgreen LE; DeFor TE; Kivisto T; Petryk A; Tolar J; Orchard PJ
    Bone Marrow Transplant; 2010 May; 45(5):939-44. PubMed ID: 19802031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT report.
    Driessen GJ; Gerritsen EJ; Fischer A; Fasth A; Hop WC; Veys P; Porta F; Cant A; Steward CG; Vossen JM; Uckan D; Friedrich W
    Bone Marrow Transplant; 2003 Oct; 32(7):657-63. PubMed ID: 13130312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
    Gossai N; Hilgers MV; Polgreen LE; Greengard EG
    Pediatr Blood Cancer; 2015 Jun; 62(6):1078-80. PubMed ID: 25556556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant osteopetrosis: hypercalcaemia after bone marrow transplantation.
    Rawlinson PS; Green RH; Coggins AM; Boyle IT; Gibson BE
    Arch Dis Child; 1991 May; 66(5):638-9. PubMed ID: 2039258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
    Goessl C; Katz L; Dougall WC; Kostenuik PJ; Zoog HB; Braun A; Dansey R; Wagman RB
    Ann N Y Acad Sci; 2012 Aug; 1263():29-40. PubMed ID: 22831177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.